Canada vs FDA / TGA / EU — Regulatory Comparison
Overview
Canada participates in the MDSAP framework alongside the US, Australia, Brazil, and Japan, and broadly follows IMDRF harmonisation principles. This means the Canadian regulatory framework is more similar to its MDSAP partners than different. However, meaningful differences exist.
Classification comparison
| Class | Canada | US FDA | Australia | EU MDR |
|---|---|---|---|---|
| Lowest risk | Class I | Class I (510(k) exempt) | Class I | Class I |
| Low-moderate | Class II | Class II (510(k)) | Class IIa | Class IIa |
| Moderate-high | Class III | Class II (PMA) / Class III | Class IIb | Class IIb |
| Highest risk | Class IV | Class III (PMA) | Class III | Class III |
Note: Mapping is approximate — exact classification of any specific device will differ across jurisdictions.
Pre-market pathways
| Element | Canada | US FDA | Australia | EU MDR |
|---|---|---|---|---|
| Pre-market authorisation | Device Licence | 510(k) / PMA / De Novo | ARTG inclusion | CE mark (Notified Body) |
| Low-risk pathway | MDEL only (Class I) | 510(k) exempt | Notified (self-declaration) | Class I self-declaration |
| Mid-risk review time | 75 days (Class III) | 90–180 days (510(k)) | 40 days (Class IIb) | 12–18 months (NB) |
| Third-party assessment | MDSAP | Third-party review (some) | TGA or conformity | Notified Body mandatory (Class IIa+) |
Post-market comparison
| Element | Canada | US FDA | Australia | EU MDR |
|---|---|---|---|---|
| Adverse event reporting | Mandatory Problem Report (MDR ss 59–64) | MedWatch (MDR) | Medical Device Incident Report (TGAMDRI) | Serious Incident Report (EUDAMED) |
| Report timeframe (death/serious) | 10/30 days | 30 days | 30 days | 15 days (unexpected) |
| Recalls | Voluntary + mandatory (s 21.3 FDA) | Voluntary + Class I/II/III | Voluntary + mandatory | Voluntary + FSCAs |
| PMS requirements | Guidance only (regulations anticipated) | 21 CFR 820 | TG226 | MDR Article 83–86 |
Bilingual labelling
Canada is unique among MDSAP jurisdictions in requiring bilingual English and French labelling. This is the most common labelling-specific barrier for manufacturers from non-bilingual markets.
MDSAP recognition
All five MDSAP jurisdictions (Canada, US, Australia, Brazil, Japan) accept MDSAP audit certificates. For a manufacturer seeking registration in all five markets, a single MDSAP audit satisfies QMS audit requirements for all jurisdictions.
Practical tips for multi-market manufacturers
- Lead with MDSAP — a single audit opens five markets
- Align clinical evidence early — design studies to meet the most stringent requirements (typically EU MDR Class III/IV), and the Canadian evidence package will be largely satisfied
- Plan bilingual labelling from the start — retrofitting French labelling is costly and delays Canadian registration
- Submit in parallel where possible — Health Canada review timelines are competitive